Search research articles
Contact Us
Filters
Showing results (251-260 of 342) with videos related to
Page
of 35
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
Rana R McKay, Amado J Zurita, Lillian Werner, et al.
Cancer Chemotherapy and Pharmacology
|
December 12, 2012
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
Luis E Raez, Kyriakos Papadopoulos, Alejandro D Ricart, et al.
Oncotarget
|
August 4, 2016
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
Christopher R Heery, Ravi A Madan, Mark N Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2014
Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial
Serena Di Cosimo, Sriram Sathyanarayanan, Johanna C Bendell, et al.
Eclinicalmedicine
|
April 28, 2025
A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function
Geeta Sandhu, Evangeline Armstrong Gordon, Josephine Adattini, et al.
Plos One
|
December 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H O'Neil, John M Wallmark, David Lorente, et al.
The Lancet. Oncology
|
June 11, 2013
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
Jan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, et al.
Investigational New Drugs
|
March 26, 2010
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium
Deborah A Bradley, Stephanie Daignault, Charles J Ryan, et al.
Prostate International
|
September 6, 2019
Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
Bertram E Yuh, Young Suk Kwon, Brian M Shinder, et al.
Nature Communications
|
December 31, 2024
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial
Mark N Stein, Ecaterina E Dumbrava, Benjamin A Teply, et al.
Page
of 35
Search research articles
Search
Showing results (251-260 of 342) with videos related to
Sort By:
Page
of 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
Rana R McKay, Amado J Zurita, Lillian Werner, et al.
Cancer Chemotherapy and Pharmacology
|
December 12, 2012
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
Luis E Raez, Kyriakos Papadopoulos, Alejandro D Ricart, et al.
Oncotarget
|
August 4, 2016
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
Christopher R Heery, Ravi A Madan, Mark N Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2014
Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial
Serena Di Cosimo, Sriram Sathyanarayanan, Johanna C Bendell, et al.
Eclinicalmedicine
|
April 28, 2025
A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function
Geeta Sandhu, Evangeline Armstrong Gordon, Josephine Adattini, et al.
Plos One
|
December 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H O'Neil, John M Wallmark, David Lorente, et al.
The Lancet. Oncology
|
June 11, 2013
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
Jan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, et al.
Investigational New Drugs
|
March 26, 2010
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium
Deborah A Bradley, Stephanie Daignault, Charles J Ryan, et al.
Prostate International
|
September 6, 2019
Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
Bertram E Yuh, Young Suk Kwon, Brian M Shinder, et al.
Nature Communications
|
December 31, 2024
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial
Mark N Stein, Ecaterina E Dumbrava, Benjamin A Teply, et al.
Page
of 35